Patent ID: 11925649
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 19:
20. A method of treating diabetic peripheral neuropathy in a subject in need thereof, the method comprising administering a composition comprising an effective amount of a selective muscarinic acetylcholine M1 receptor antagonist selective for the M1 receptor, wherein administration reduces diabetic peripheral neuropathy in the subject,
wherein the selective muscarinic acetylcholine M1 receptor antagonist is selected from the group consisting of: VU255035, pirenzepine, telenzepine, atropine, MT7, PD150714, trihexyphenidyl, p-fluotrihexyphenidyl, O-methoxy-sila-hexocyclium, spirotramine, McN-A-343, McN-A-343 analog, MB-OXTP, nitrocaramiphen, aprophen, (−)-S-ET126, N-desmethylclozapine, MDL74019DG, glycopyrronium bromide, dicyclomine, and salts thereof; and
wherein administration comprises topical application, oral delivery, subcutaneous injection, or intravenous injection.